Findings

What do systematic reviews say?

167 questions · 170 findings · 8 reviews

No studies found 21 · 12.4%GRADE not reported 0 · 0%Very low 7 · 4.1%Low 34 · 20%Moderate 84 · 49.4%High 24 · 14.1%

Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer

The intervention may leads to higher grade 3 to 4 diarrhoea (low certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
OR 2.58 [1.44, 4.64]
5 studies · 2434 participants
Low

Grade 3 to 4 neutropenia · people with metastatic colorectal cancer ‐ KRAS exon 2 WT

The intervention showed no clear difference in grade 3 to 4 neutropenia (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
OR 1.22 [0.93, 1.61]
6 studies · 2666 participants
Moderate

Grade 3 to 4 rash · people with metastatic colorectal cancer

The intervention probably leads to higher grade 3 to 4 rash (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
OR 67.52 [30.83, 147.85]
4 studies · 2363 participants
Moderate

Grade 3 to 4 neutropenia · people with metastatic colorectal cancer

The intervention showed no clear difference in grade 3 to 4 neutropenia (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
OR 0.97 [0.73, 1.29]
2 studies · 1187 participants
Moderate

Quality of life · people with metastatic colorectal cancer

The review found no eligible studies for this question.

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Quality of life · people with metastatic colorectal cancer ‐ KRAS exon 2 WT

The intervention probably leads to lower quality of life (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 2258 participants
Moderate

Progression‐free survival · people with metastatic colorectal cancer ‐ KRAS exon 2 MT

The intervention showed no clear difference in progression‐free survival (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 1.03 [0.89, 1.2]
8 studies · 2567 participants
Moderate